Credit Suisse Maintains Outperform on Olema Pharmaceuticals, Lowers Price Target to $11
Credit Suisse analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price target from $12 to $11.
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $15
HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $12 to $15.
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability With CDK 4/6 Inhibitor Palbociclib In Phase 1b Dose Escalation Study
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction
No induced metabolism of palbociclib
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Autolus Therapeutics (NASDAQ:AUTL) stock moved upwards by 15.0% to $2.3 during Tuesday’s after-market session. The market value…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
PLx Pharma (NASDAQ:PLXP) stock increased by 15.5% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $20.3 million.
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Recap of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset…
Olema Oncology Advances OP-1250 Into Phase 2 Monotherapy Expansion In Patients With ER+/HER2- Advanced Breast Cancer
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), today announced the advancement of OP-1250, a complete estrogen receptor
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
Gainers
Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending on January 17, 2023.